Side-by-side · Research reference
ProstamaxvsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/38 cited
BPhase 3HUMAN-REVIEWED25/54 cited
Prostamax
Khavinson Bioregulator · Tissue-Specific Peptide
4 AAPeptide length
SQ · Protocol per Khavinson tradition
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
Prostamax
Survodutide
Primary target
Chromatin in prostatic cells — pericentromeric heterochromatin regions
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012Zakutskiĭ 2006
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
—
—
Origin
Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017
—
Antibody development
—
—
02Dosage Protocols
Parameter
Prostamax
Survodutide
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic culture model; demonstrated tissue-specific stimulation.
—
Human clinical dose
Not established
No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).
—
Evidence basis
Animal / organotypic cultureZakutskiĭ 2006Dzhokhadze 2012
No randomized controlled trials in humans.
Phase 2 RCT (obesity) · Phase 3 ongoing
Age groups studied
Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006Dzhokhadze 2012
—
Duration
Not specified
Khavinson protocols typically 10–20 days per cycle; no long-term safety data.
—
Frequency
—
Once weekly
03Metabolic / Fat Loss Evidence
Parameter
Prostamax
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
Prostamax
Survodutide
Published adverse events
None reported in available literature
—
Genotoxicity signals
Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications
—
Metal ion interactions
Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance
—
Human safety data
Absent — no published Phase 1/2/3 trials
—
GI symptoms
—
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
Prostamax
- ·Active prostate malignancy — epigenetic modulation effects unknown in cancer
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
Prostamax
- ·History of prostate cancer — theoretical concern re: transcriptional activation
- ·Undiagnosed prostatic nodules or elevated PSA
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
Prostamax
Survodutide
1. Route
Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Reconstitution
If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Frequency
Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Monitoring
No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Note
All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.